FDA Drug Safety Podcast: Update: FDA evaluating the risk of burns and scars with Zecuity (sumatriptan) migraine patch

On June 10, 2016, Zecuity manufacturer, Teva Pharmaceuticals, announced it has decided to temporarily suspend sales, marketing, and distribution to investigate the cause of burns and scars associated with the Zecuity patch.

Source: FDA Drug Safety Podcasts - June 21, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts